Inner Circle Forums
Portions of the Undoctored Inner Circle Member Forum and its vast wealth of knowledge, are available only to our Members.
Becoming an Inner Circle Member will allow you to post topics, ask Dr. Davis questions, and view all replies.


2010. Zetia significant improvement___Fatty liver diabete II dyslipidemia, inflammation, apoB, LDL


Member Forum >> UnKnown >> 2010. Zetia significant improvement___Fatty liver diabete II dyslipidemia, inflammation, apoB, LDL

Join Date: 12/20/2007
Posts Contributed: 17383
Total Likes: 6
Recommends Recd: 0
Ignores Issued: 0
Likes Recd: 0


Effect of Ezetimibe on Hepatic Fat, Inflammatory Markers, and Apolipoprotein B-100 Kinetics in Insulin-Resistant Obese Subjects on a Weight Loss Diet

  1. Dick C. Chan, PHD,
  2. Gerald F. Watts, MD, DSC,
  3. Seng Khee Gan, MD, PHD,
  4. Esther M.M. Ooi, PHD and
  5. P. Hugh R. Barrett, PHD

+ Author Affiliations

  1. From the Metabolic Research Centre, School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia, Australia.
  1. Corresponding author: Gerald F. Watts, gerald.watts@uwa.edu.au.

Abstract

OBJECTIVE Nonalcoholic fatty liver disease is highly prevalent in obese and type 2 diabetic individuals and is strongly associated with dyslipidemia and inflammation. Weight loss and/or pharmacotherapy are commonly used to correct these abnormalities.

RESEARCH DESIGN AND METHODS We performed a 16-week intervention trial of a hypocaloric, low-fat diet plus 10 mg/day ezetimibe (n = 15) versus a hypocaloric, low-fat diet alone (n = 10) on intrahepatic triglyceride (IHTG) content, plasma high sensitivity–C-reactive protein (hs-CRP), adipocytokines, and fetuin-A concentrations and apolipoprotein (apo)B-100 kinetics in obese subjects. ApoB-100 metabolism was assessed using stable isotope tracer kinetics and compartmental modeling; liver and abdominal fat contents were determined by magnetic resonance techniques.

RESULTS Both weight loss and ezetimibe plus weight loss significantly (all P < 0.05) reduced body weight, visceral and subcutaneous adipose tissues, insulin resistance and plasma triglycerides, VLDL–apoB-100, apoC-III, fetuin-A, and retinol-binding protein-4 and increased plasma adiponectin concentrations. Compared with weight loss alone, ezetimibe plus weight loss significantly (all P < 0.05) decreased IHTG content (−18%), plasma hs-CRP (−53%), interleukin-6 (−24%), LDL cholesterol (−18%), campesterol (−59%), and apoB-100 (−14%) levels, with a significant increase in plasma lathosterol concentrations (+43%). The LDL–apoB-100 concentration also significantly fell with ezetimibe plus weight loss (−12%), chiefly owing to an increase in the corresponding fractional catabolic rate (+29%). The VLDL–apoB-100 secretion rate fell with both interventions, with no significant independent effect of ezetimibe.

CONCLUSIONS Addition of ezetimibe to a moderate weight loss diet in obese subjects can significantly improve hepatic steatosis, inflammation, and LDL–apoB-100 metabolism.




This is precisely part of my diabetic brother's program as he reduced his CAC score of 17 to zero in three years. He took Lipitor 40 mg  and Zetia 10.  He weight once in excess 290 bs.  AST, ALT way whacked up'D. Fatty liver.

Dr. Jgoldstrich

If Zetia was prohibitive in any ways to the positive benefit of lipitor 40 mg____there would have been absolutely no way for the CAC score of 17 reduction to zero to occur.
   Brother has no Lp(a) problem.


Tags:


DISCLAIMER

The information contained within this Forum and website is of a general nature and intended purely as background reading for the participants taking part in Forum discussions and projects. It should not be construed as professional medical advice. Please read the website Medical Disclaimer for more information and limitations.

Changes may occur in circumstances at any time that may affect the accuracy or completeness of the information presented within any section of the Forum and website. This Forum and Track Your Plaque, LLC have taken reasonable care in producing and presenting the content contained herein, however, we do not accept responsibility for any loss, expense, or liability that you may incur from using or relying on the information sourced from this website, its forums and/or blogs.

Third-party content and links

This Forum and Track Your Plaque, LLC accept no responsibility for the accuracy of third-party content or links, or your reliance on any information contained within any such content available through our site. The comments published on this Forum represent a wide range of views and interests of the participating individuals and organizations. Statements made during online discussions are the personal opinions of the commentators and do not necessarily reflect those of others participating on this Forum. Track Your Plaque, LLC at all times and at its absolute discretion, reserves the right to remove reasonably offensive comments in line with our Moderation Guidelines.